Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Research & Development (2016 - 2025)

Guided Therapeutics' Research & Development history spans 15 years, with the latest figure at $136000.0 for Q3 2025.

  • For Q3 2025, Research & Development rose 22.52% year-over-year to $136000.0; the TTM value through Sep 2025 reached $483000.0, up 2.11%, while the annual FY2024 figure was $526000.0, 130.7% up from the prior year.
  • Research & Development for Q3 2025 was $136000.0 at Guided Therapeutics, up from $133000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $222000.0 in Q2 2024 and bottomed at $7000.0 in Q1 2023.
  • The 5-year median for Research & Development is $54000.0 (2024), against an average of $65473.7.
  • The largest YoY upside for Research & Development was 762.5% in 2023 against a maximum downside of 66.67% in 2023.
  • A 5-year view of Research & Development shows it stood at $17000.0 in 2021, then soared by 129.41% to $39000.0 in 2022, then soared by 120.51% to $86000.0 in 2023, then soared by 62.79% to $140000.0 in 2024, then fell by 2.86% to $136000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Research & Development are $136000.0 (Q3 2025), $133000.0 (Q2 2025), and $74000.0 (Q1 2025).